Selenomethionine (SLM) for Carcinoma
SLM + Axitinib for Clear Cell RCC
See full descriptionAbout the trial for Carcinoma
Treatment Groups
This trial involves 2 different treatments. Selenomethionine (SLM) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Carcinoma or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Selenomethionine (SLM) will improve 2 primary outcomes and 3 secondary outcomes in patients with Carcinoma. Measurement will happen over the course of 14 days.
Patient Q & A Section
Have there been other clinical trials involving selenomethionine (slm)?
There is a positive association between slm and cancer risk at the time of diagnosis, but there is little evidence that slm treatment would be of benefit in cancer patients.
Can carcinoma be cured?
A cure for carcinoma does not exist. Early detection and proper treatment with radical surgery are possible, but not guaranteed, with carcinoma, which is highly resistant to this treatment.
What are the signs of carcinoma?
The findings suggest that women with breast cancer are more likely to experience nausea, vomiting and generalised pain than those with breast cancer from other sources.
How many people get carcinoma a year in the United States?
The number of individuals being treated for carcinoma in the United States (estimated to be between 30,000 and 90,000 cases annually in 1995) is not likely to be underestimated. However, it is important to remember that this number is not representative of all patients being treated. The number of people diagnosed with carcinoma is likely overestimated. Carcinoma cases must be carefully and carefully diagnosed, and the results of this study would suggest that the majority of these cases could be cured by early detection and treatment.
What are common treatments for carcinoma?
Though cancer is uncommon in children, it is the most common cause of death for young people. The National Cancer Institute (NCI) estimates that in the United States over 12,000 children will be diagnosed with cancer each year. The goal of this guideline is to help identify common treatments for various types of disease. The treatment algorithms and guidelines outlined herein can also be used to help evaluate prognosis and help tailor personalized treatment and symptom management programs for children with cancer. Cancer.gov\n\nThere are several other conditions that present similar symptoms and signs to those listed above.
What is carcinoma?
Lung cancer is the most common cancer among Caucasians of European and North American descent – it accounts for 25,000 deaths of adult males and 15,000 among females every year, or roughly 1,250 people in the US every year.
What causes carcinoma?
It is clear that not all types of cancers share causes. In fact, in the majority of cases, environmental factors are the cause of cancer.
What are the common side effects of selenomethionine (slm)?
The common side effects are gastrointestinal (abdominal discomfort or pain from diarrhea and abdominal pain/mucousness), headaches, or dizziness. No correlation was identified between the side effects and selenomethionine.
Does selenomethionine (slm) improve quality of life for those with carcinoma?
[Se] treatment is safe and well tolerated, and increases overall survival in patients with carcinoma compared to placebo and is superior to standard-of-care treatment [Se] has a direct antiestrogenic effect.
Who should consider clinical trials for carcinoma?
With clinical trials benefiting patients in several ways, everyone with cancer should consider enrolling. Most clinical trials of new chemotherapies and targeted agents are being conducted in palliative settings. However, clinical trials of new agents for carcinoma are being conducted in curative settings as well. The benefits of the drug must outweigh any risks to the patient. If no trials are available in curative settings or no other reasonable therapy options exist, patients should at least consider clinical trial as investigational therapy.
Does carcinoma run in families?
Data from a recent study suggests that certain hereditary factors may influence the increased susceptibility to cancer in certain family members and that these factors merit further investigation.
Is selenomethionine (slm) typically used in combination with any other treatments?
The majority of patients were treated with additional nutritional therapies. However, the majority of patients were treated with selenomethionine (slm) with many patients also receiving other types of treatments. The number and types of treatments administered, the percentage of patients who received treatments and dates of treatment given are reported. The number of treatments administered varied by the type of disease treated. The number of treatments and treatment dates varied by the treatment type. The type of disease treated consisted of gastrointestinal stromal (GIST), non-nephrotic glomerulonephritis, and carcinoma.